The IL-36 Pathway and Pustular Psoriasis
The IL-36 Pathway and Pustular Psoriasis
The IL-36 Pathway and Pustular Psoriasis
Signaling
No signaling
Uncontrolled inflammatory signalling, resulting from IL-36 receptor antagonist (IL-36RA) dysfunction or
over-expression of IL-36 agonists, can lead to autoinflammatory skin diseases, such as generalized pustular
psoriasis (GPP) and palmoplantar pustulosis (PPP) – types of pustular psoriasis.2,5-8
GPP
Trigger (pustules and skin inflammation)
Dysfunctional
IL-36RA or
over-expression Neutrophil
of IL-36 agonists recruitment
Cytokines and
more T-cells
While pustular psoriasis and plaque psoriasis are distinct conditions, driven by separate underlying pathways,
crosstalk between these pathways can sometimes lead to a vicious cycle of inflammation and mutually
reinforced disease.2,7,9-11
Boehringer Ingelheim is committed to transforming the lives of people living with autoinflammatory diseases,
such as pustular psoriasis, through understanding how faults occur in the immune system and developing
treatments to blunt an overactive inflammatory response, block further damage and repair damage caused.
References:
Definitions: 1. Ngo Vu L, et al. PNAS. 2018;115(22). 2. Gabay C, et al. J Leukoc
Biol. 2015;97(4):645-52. 3. Ganesan R, et al. mAbs. 2017;9:1143-54.
Agonists: molecules that bind to a receptor to activate a biological response 4. Bassoy EY, et al. Immunol Rev. 2018;281:169-78. 5. Marrakchi
S, et al. N Engl J Med. 2011;365:620-8. 6. Sugiura K, et al. J Invest
Antagonists: molecules that bind to a receptor or a cytokine to block or inhibit Dermatol. 2013;133:2514-21. 7. Furue K, et al. Acta Derm Venereol.
a biological response 2018;98(1):5-13. 8. Johnston A, et al. J Allergy Clin Immunol. 2017
July;140(1):109–120. 9. Schön M, et al. Front Immunol. 2018;9:1323.
Cytokines: molecules involved in cell signalling and the immune response 10. Pfaff CM, et al. Sci Rep. 2017;7:15631. 11. Liang Y, et al. Curr Opin
Immunol. 2017;49:1-8.